Makefield Therapeutics Appoints Jim Ballance Chief Scientific Officer

Makefield Therapeutics Appoints Jim Ballance Chief Scientific Officer  
NEWTOWN, Pa. - (Business Wire) Makefield Therapeutics, Inc., an emerging pharmaceutical company, today announced the appointment of Jim Ballance, Ph.D., as Chief Scientific Officer. Dr. Ballance, most recently a corporate strategic consultant to the biotechnology industry, is an experienced technology and corporate development professional whose career has included senior management positions at both large and small companies in the United States and United Kingdom.

"Jim Ballance joins Makefield with over 20 years of experience in the development and manufacturing of novel therapeutics," said Robert J. Towarnicki, President and Chief Executive Officer of Makefield Therapeutics. "He joins us with a solid track record in building strong pipelines and successful partnering strategies that added significant value to the companies where he worked. Jim's skills will be invaluable as we seek to advance our own products based on our novel nanoparticle drug delivery platform and additionally look for partners to employ this innovative technology in areas outside our own interests."

Dr. Ballance's experience includes such positions as Vice President, Technology Development, at BioRexis Pharmaceutical Corp.; Director of Biotechnology Evaluation, Aventis Behring LLC; Chief Technology Officer, Genesis Therapeutics; and Head of R&D, Delta Biotechnology Ltd. He received his Ph.D. from the University of Bristol, U.K.

About Makefield Therapeutics, Inc.

Makefield Therapeutics, Inc., founded in July 2009, is a privately held therapeutics company with two development programs addressing large market opportunities in anti-infectives and the treatment of erectile dysfunction. Both programs are based on an innovative nanoparticle drug delivery platform with the potential to generate a pipeline of additional novel therapeutics. For more information on the company, please visit our website at http://www.makefieldtherapeutics.com.

 

 

Makefield Therapeutics, Inc.
Robert J. Towarnicki, 215-321-5713
President and CEO
[email protected]
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413 (Media)
Mob: 415-690-0210
[email protected]

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.